Students Earn Top Awards at 42nd Annual Research Science Institute at MIT
The original release is unavailable here.
Regeneron Pharmaceuticals, Inc. on 6ix
Earlier from Regeneron Pharmaceuticals
- Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)
- Regeneron Reports Second Quarter 2025 Financial and Operating Results
- Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation
- Top science teachers announced for 12th annual Regeneron STEM teaching fellowship
- Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma
Later from Regeneron Pharmaceuticals
- EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension
- Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
- Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
- Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
- Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Follow Regeneron Pharmaceuticals into a list and get an email when it puts out news.
Follow Regeneron Pharmaceuticals